Radioimmunotherapy of Cancer Using Monoclonal Antibodies to Target Radiotherapy

Author(s): Timothy M. Illidge, Susannah Brock

Journal Name: Current Pharmaceutical Design

Volume 6 , Issue 14 , 2000

Become EABM
Become Reviewer
Call for Editor


After years of pre-clinical and clinical testing monoclonal antibodies (mAbs) finally offer new therapeutic choices for patients with haematological and solid malignancies both as unconjugated antibody and as vectors to target radionuclides in radioimmunotherapy (RIT). In recent years some of the most exciting clinical data have come from the use of RIT in the treatment of lymphoma and haematological malignancies and it would now appear highly likely that RIT will play a major role in the treatment strategies for these diseases. For the solid tumours there has also been considerable progress with RIT and mAbs have become a component of treatment protocols for breast cancer. This review highlights the important recent clinical progress that has been made with clinical RIT and provides some new insights into the important mechanisms of action of RIT in haematological malignancies.

Keywords: Target radiotherapy, monoclonal antibodies (mAbs), Radioimmunotherpy (RIT), Haematological malignancies, ADCC, Antibodies, Tumour nodules, HAMA response, Immunosuppression, Cyclosporin, Deoxysperualin, The Radioisotope, Radioimmunoglobulin, Normal tissue toxicity, Dosimetry, MIRD, Non myeloablative therapy in lymphoma, CD20 antibodies, Phase II pivotal, Complete response, Maximum Tolerated Dose, Immunoglobulin idiotype, IDEC Y2B8, Solid tumours

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2000
Page: [1399 - 1418]
Pages: 20
DOI: 10.2174/1381612003399257
Price: $65

Article Metrics

PDF: 6